Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bluejay Diagnostics, Inc. (BJDX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing insight into its development of the Symphony near-patient testing platform and Symphony IL-6 Test for sepsis triage and monitoring. As an emerging growth company listed on The Nasdaq Capital Market, Bluejay files periodic and current reports that describe its clinical, manufacturing, financing, and governance activities.
Through Forms 10-K and 10-Q, investors can review Bluejay’s descriptions of the Symphony System, its regulatory plans for a 510(k) submission for the Symphony IL-6 test, and discussions of risks, liquidity, and capital requirements. Current reports on Form 8-K detail material events such as amendments to the Master Service Agreement and Master Supply Agreement with SanyoSeiko Co., Ltd., changes to license and supply arrangements with Toray Industries, Inc., private placements of common stock, pre-funded warrants and Series F warrants, and the implementation of a 1-for-50 reverse stock split.
This page also provides access to exhibits referenced in Bluejay’s 8-K filings, including forms of warrants, securities purchase agreements, registration rights agreements, and amendments to key manufacturing and licensing contracts. These documents help explain how Bluejay is structuring its manufacturing partnerships, securing access to cartridge components, and arranging financing to support clinical trials and regulatory activities for the Symphony IL-6 test.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, such as how a particular financing affects share structure or how a contract amendment changes manufacturing responsibilities. Users can quickly identify disclosures related to capital raises, reverse stock splits, material agreements, and other events without reading every page of the underlying filing. Real-time updates from EDGAR ensure that new Bluejay filings, including any future proxy statements or insider transaction reports, are added as they become available, giving investors a structured view of BJDX’s regulatory history and ongoing obligations.